Extendicare Announces 2026 Third Quarter Results
Markham, Ontario--(Newsfile Corp. - November 5, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") today reported results for the three and nine months ended September 30, 2026. Third Quarter 2026 Highlights Adjusted EBITDA(1) of $71.7 million, up $20.9 million or 41.2% from Q3 2025. Net earnings of $34.2 million ($0.354 per diluted share), up $10.1 million or 41.8% from $24.1 million ($0.
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-11-05 5:00 PM EST | Extendicare Inc.
TelyRx Announces Third Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - November 5, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a technology-enabled healthcare and digital pharmacy platform, today announced financial results for the third quarter ended September 30, 2026. All dollar amounts are expressed in U.S. dollars. Highlights for the Third Quarter of 2026 Revenue increased to $23.1 million, com
Soins de santé et hôpitaux, Santé
2026-11-05 4:45 PM EST | TelyRx
Doseology Announces Revocation of MCTO and Adoption of Semi-Annual Financial Reporting
Kelowna, British Columbia--(Newsfile Corp. - November 5, 2026) - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") announces revocation of the management cease trade order ("MCTO") previously issued on October 29, 2026; and its intention to voluntarily adopt the Semi-Annual Reporting ("SAR") Pilot Program pursuant to Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Ventu
2026-11-05 4:30 PM EST | Doseology Sciences Inc.
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
King of Prussia, Pennsylvania--(Newsfile Corp. - November 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutic products based on its proprietary INTASYL® gene-silencing technology to eliminate cancer, today reported financial results for the quarter ended September 30, 2026, and provided a business update. "We have successfully executed on critical development objectives to advance the PH-762 program towa
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-11-05 4:05 PM EST | Phio Pharmaceuticals Corp.
Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury
Ness Ziona, Israel--(Newsfile Corp. - November 5, 2026) - Matricelf Ltd. (TASE: MTLF), a biotechnology company develo
2026-11-05 11:31 AM EST | Matricelf Ltd.
AAMI Foundation Receives $50,000 Contribution from DuPont to Expand the Dr. Michael Scholla Packaging Engineering Scholarship Fund
Arlington, Virginia--(Newsfile Corp. - November 5, 2026) - The AAMI Foundation today announced it has received a $50,000 contribution from DuPont to help expand the Dr. Michael Scholla Packaging Engineering Scholarship fund. The Scholarship, created by the AAMI Foundation in partnership with DuPont Tyvek® Healthcare Packaging and Beacon Converters, Inc., is a $3,000 annual award that supports undergraduate and graduate
2026-11-05 10:51 AM EST | Association for the Advancement of Medical Instrumentation
BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that Ralph Anthony ("Tony") Pullen has resigned from the Company's Board of Directors, effective November 4, 2026, and will remain with the Company as an advisor. The Board has appointed Henry Chow, CPA, CA, as a d
2026-11-05 8:00 AM EST | BetterLife Pharma Inc.
Apptly Health Completes National Rebrand from UberDoc; Launches Paid Physician and Healthcare Partner Memberships
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (OTCQB: APTHF) (the "Company" or "Apptly") today announced that its direct-pay specialist marketplace, previously operated under the UberDoc brand, is now live nationally as Apptly Health on a rebuilt web platform (apptlyhealth.com). With this launch, physicians and healthcare marketpla
2026-11-05 7:00 AM EST | Apptly Health Technologies Corp.
Cheelcare Announces Departure of Co-Founder and Director
Markham, Ontario--(Newsfile Corp. - November 4, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced that co-founder Dima Paltsev has completed his transition of executive responsibilities, effective November 1, 2026, and will conclude his service on the Company's Board of Directors at its upcoming Annual General Meeting on November 13, 2026, to pursue an independent business venture focused on ro
2026-11-04 7:30 AM EST | Cheelcare Inc.
Medexus Schedules Second Fiscal Quarter 2027 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 12, 2026, to discuss Medexus's results for its second fiscal quarter ended September 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on November 11, 2026. To participate in the call, please dial the following numbers:
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-11-03 5:27 PM EST | Medexus Pharmaceuticals Inc.
Custom Health Files Preliminary Short Form Base Shelf Prospectus and Refiles Certain Continuous Disclosure Documents
Kelowna, British Columbia--(Newsfile Corp. - November 3, 2026) - Custom Health Holdings Inc. (TSX: CHLT) ("Custom Health" or the "Corporation") is pleased to announce that it has filed a preliminary short form base shelf prospectus with the securities commissions in each of the provinces and territories of Canada. The base shelf prospectus, when made final and effective, will allow the Corporation to qualify the distribution by way of prospectus in
Technologies, Pharmaceutique, Santé
2026-11-03 5:00 PM EST | Custom Health Holdings Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial
Toronto, Ontario--(Newsfile Corp. - November 3, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Healt
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-11-03 8:02 AM EST | Rhelion Life Sciences Corp.
Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq.
Northvale, New Jersey--(Newsfile Corp. - November 3, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that on October 28, 2026, its Board of Directors (the "Board") increased the size of the Board from four to six directors and unanimously elected Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq. as directors. "We are pleased to welcome Aqeel Fatmi and John LaRocca to
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-11-03 7:30 AM EST | Elite Pharmaceuticals, Inc.
Neural Therapeutics Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - November 2, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces a change to its Board of Directors and provides updates regarding its previously announced transaction with CWE European Holdings Inc. ("CWE"). Board of Directors The Company announces that John Durfy has resigned as Chairman and a director of the Company, effective October 26, 2026. The Company thanks Mr.
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-11-02 8:30 PM EST | Neural Therapeutics Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing
Toronto, Ontario--(Newsfile Corp. - November 2, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-11-02 7:37 AM EST | Rhelion Life Sciences Corp.
TempraMed Signs Exclusive UK Distribution Agreement with Poole Bay Holdings for VIVI Epi(TM), Targeting School Networks Across the UK
Highlights Definitive agreement signed October 28, 2026 appoints Poole Bay Holdings Ltd. as exclusive UK distributor of VIVI Epi™ for an initial 24-month term, subject to UK regulatory requirements. Contractual minimum purchase to maintain exclusivity. The initial two-year minimum volumes represent approximately US$198,000 in potential purchases. Poole Bay Holdings reports 20 specialist e-commerce sites an
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-11-02 7:00 AM EST | TempraMed Technologies Ltd.
Rapid Dose Announces Proposed Debt Settlement
Burlington, Ontario--(Newsfile Corp. - October 30, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") announces that it has agreed with certain of its creditors (the "Creditors") to issue up to an aggregate of 5,000,000 common shares (the "Settlement Shares") to such Creditors in exchange for the cancellation of outstanding accounts payable (the "Shares for Debt Transaction") in the aggregate amount of up to $500,0
2026-10-30 4:19 PM EDT | Rapid Dose Therapeutics Corp.
Mobile-health Network Solutions Launches MaNaDr Health Operating Ecosystem Connecting AI-Powered Virtual and In-Person Care
Singapore, Singapore--(Newsfile Corp. - October 30, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health ecosystem, today announced that the MaNaDr Health Operating Ecosystem is scheduled to launch first in Singapore on November 2, 2026, followed by a phased global rollout over the following two months. Developed over two and a half years, the ecosystem combines MaNaDr's patient-facing virtual care platform with OtterSG's
2026-10-30 8:10 AM EDT | Mobile-health Network Solutions
Mobile-health Network Solutions Reports FY2026 Results, Highlights Investments in AI, Advances Ghana Expansion, and Launches MaNaDr Health Operating Ecosystem for Global Rollout
Singapore, Singapore--(Newsfile Corp. - October 30, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health ecosystem headquartered in Singapore, today announced its financial and operating results for the fiscal year ended June 30, 2026, highlighting the positive impact of its strategic investments in artificial intelligence, its expansion into Africa, and the continued development of new technology partnerships expected to
2026-10-30 8:00 AM EDT | Mobile-health Network Solutions
WELL Health to Announce Third Quarter 2026 Financial Results on November 9, 2026
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Third Quarter 2026 financial results for the period ended September 30, 2026, after
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-10-30 6:00 AM EDT | WELL Health Technologies Corp.